NG13

Prevention of chemotherapy-induced alopecia (hair loss)

Status: Formulation Development Underway​

Around 40% of all cancer patients receive chemotherapy, of whom approximately 65% develop hair loss as a result.

In addition, a majority of patients who receive radiation therapy to the head region develop hair loss.

Existing “Cold cap” solutions require special equipment and lengthy treatment times, and are associated with scalp pain.

NG13 represents a faster-acting, topical pharmaceutical solution with substantial quality of life benefits.